[18F]fallypride PET measurement of striatal and extrastriatal dopamine D2/3 receptor availability in recently abstinent alcoholics
[18F]fallypride PET measurement of striatal and extrastriatal dopamine D2/3 receptor availability in recently abstinent alcoholics
复制标题
DOI：
10.1111/j.1369-1600.2011.00355.x
复制
发表时间：
2010-05
影响因子：
3.4
通讯作者：
A. Rominger;P. Cumming;G. Xiong;G. Koller;G. Böning;M. Wulff;A. Zwergal;S. Förster;A. Reilhac;O. Munk;M. Soyka;B. Wängler;P. Bartenstein;C. la Fougère;O. Pogarell
中科院分区：
文献类型：
--
作者：
A. Rominger;P. Cumming;G. Xiong;G. Koller;G. Böning;M. Wulff;A. Zwergal;S. Förster;A. Reilhac;O. Munk;M. Soyka;B. Wängler;P. Bartenstein;C. la Fougère;O. Pogarell
正电子发射断层扫描 (PET) 显示戒断精神兴奋剂滥用者纹状体中多巴胺 D2/3 拮抗剂 [11C]雷氯必利的结合减少，但在酒精依赖 (AD) 患者中情况并非如此。我们首先使用高亲和力配体 [18F]fallypride 来获得正在进行戒毒的 AD 患者纹状体和纹状体外区域 D2/3 受体可用性的系列测量。 17 名 AD 患者（平均年龄 44 ± 5 岁）和 14 名年龄匹配的健康志愿者参与了研究。每名患者在入院时均接受[18F]fallypride PET检查，并在1-2周后再次接受检查；两名患者实现了戒断，两名患者的危害显着减少，并在 1 年时进行了额外的 PET 随访。动态 180 分钟 PET 记录用于 [18F]fallypride 结合电位 (BPND) 的基于感兴趣体积 (VOI) 和体素分析。 AD患者纹状体平均基线BPND（15.7±3.6）在短期随访期间没有变化，与健康对照者（16.8±3.0）没有差异；然而，AD 患者的丘脑、海马、岛叶和颞叶皮质的 BPND 降低了 10-20%（P < 0.05）。在对照组中，BPND 随年龄的下降非常小，但在 AD 组中更为明显和广泛。 4 名长期戒酒或减少饮酒的患者的纹状体和丘脑 BPND 增加了 30%。基于 VOI 的 [18F]fallypride PET 分析揭示了主要在纹状体区域的 D2/3 受体可用性的群体差异。 AD 患者中与年龄相关的多巴胺 D2/3 受体丧失更为明显。受体的可用性并未因急性戒断而改变，但在长期随访的患者亚组中有所增加，表明受体变化的可逆性。
Positron emission tomography (PET) shows reduced binding of the dopamine D2/3 antagonist [11C]raclopride in striatum of withdrawn psychostimulant abusers, but not consistently in patients with alcohol dependence (AD). We make first use of the high affinity ligand [18F]fallypride to obtain serial measures of D2/3 receptor availability in striatal and extrastriatal regions of AD patients undergoing detoxification. Seventeen patients (mean age 44 ± 5y) with AD and 14 age‐matched healthy volunteers participated. Each patient underwent [18F]fallypride PET upon hospital admission, and again 1–2 weeks later; two patients achieving abstinence, and two with substantial harm reduction had additional PET follow‐up at 1 year. Dynamic 180‐minute PET recordings were used for volume of interest (VOI)‐based and voxel‐wise analysis of [18F]fallypride binding potential (BPND). Mean baseline BPND in striatum of the AD patients (15.7 ± 3.6) was unaltered during short‐term follow‐up, and did not differ from that in healthy controls (16.8 ± 3.0); however, BPND was 10–20% lower in thalamus, hippocampus, and insular and temporal cortex of the AD patients (P < 0.05). Age‐dependent declines in BPND were very small in controls, but more pronounced and widespread in the AD group. Striatal and thalamic BPND increased by 30% in four patients with long‐term abstinence or reduced alcohol consumption. VOI‐based [18F]fallypride PET analyses revealed group differences in D2/3 receptor availability primarily in extra‐striatal regions. Age‐related loss of dopamine D2/3 receptors was more pronounced in AD patients. Receptor availability was unaltered by acute withdrawal, but increased in the subgroup of patients with long‐term follow‐up, suggesting reversibility of receptor changes.